SEC Form SC 13G filed by Kymera Therapeutics Inc.
$KYMR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/6/2026 | $106.00 | Buy | Canaccord Genuity |
| 3/16/2026 | Buy | Jefferies | |
| 1/28/2026 | $133.00 | Overweight | Barclays |
| 1/6/2026 | Outperform → Peer Perform | Wolfe Research | |
| 11/3/2025 | $90.00 | Buy | Guggenheim |
| 10/24/2025 | $60.00 → $80.00 | Buy | B. Riley Securities |
| 10/21/2025 | $81.00 | Outperform | Mizuho |
| 9/18/2025 | $60.00 → $70.00 | Buy | H.C. Wainwright |
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
SCHEDULE 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
WATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on June 3, 2026, at 8:10 a.m. ET. A live webcast of the presentation will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pion
WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: Bank of America 2026 Healthcare Conference in Las Vegas, NV on May 12 at 9:20 a.m. PT; andRBC Capital Markets 2026 Global Healthcare Conference in New York, NY on May 19 at 9:00 a.m. ET. Live webcasts of the presentations will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. Replays of the webcast
KT-579 demonstrated activity comparable or superior to approved and clinically active therapies in preclinical IBD models KT-579 Phase 1 healthy volunteer trial ongoing, with data expected in 2H26 WATERTOWN, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the presentation of new preclinical data for KT-579, its potent, selective, oral IRF5 degrader, demonstrating disease-modifying activity in an inflammatory bowel disease (IBD) model. The findings show that by selectively targeting and degrading IRF5, KT-57
Canaccord Genuity initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $106.00
Jefferies resumed coverage of Kymera Therapeutics with a rating of Buy
Barclays resumed coverage of Kymera Therapeutics with a rating of Overweight and set a new price target of $133.00
Highly experienced partners bringing 25+ years of leadership across top-tier life-sciences investment fund, pharma and Biopharma companies, driving accelerated portfolio development With leadership experience at Blackstone Life Sciences (Deputy Chief Operating Officer), Biogen, (NASDAQ:BIIB), and public and private Biopharma companies (including Kymera Therapeutics (NASDAQ: KYMR) and Cygnal Therapeutics), Elaine Caughey will support portfolio companies in strengthening operational execution, defining robust market access pathways, and enhancing their strategic value through business development support, including partnerships and acquisition transactions. She will also draw on her know
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Brian Adams, JD, as Chief Legal Officer and Corporate Secretary. Mr. Adams is a highly accomplished legal executive with nearly two decades of leadership in the life sciences, spanning corporate development, strategic planning, and governance. He will lead Kymera's legal, governance, and intellectual property functions. Mr. Adams will succeed Ellen Chiniara who is retiring from her role to focus on board service, mentoring and oth
WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-621 in healthy volunteers on Monday, June 2, 2025. The Company will host a video webcast at 8:00 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast and copy of the presentation will be a
SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to KT-621 for the treatment of moderate to severe asthma, in addition to prior Fast Track designation for moderate to severe atopic dermatitis KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 2H26 Gilead Sciences exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader, generating a $45 million milestone, with IND planned in 2027 Well-capitalized with $1.55 billion in cash as of March 31, 2026, and runway into 2029 Co
WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report first quarter 2026 financial results on April 30, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Kymera Therapeutics Kymera is a clinical-stage
KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 (IRF5) Phase 1 healthy volunteer trial with data expected in 2H26 Dr. Neil Graham, experienced biopharma leader, appointed Chief Development Officer Well-capitalized with $1.6 billion in cash as of December 31, 2025, and runway into 2029 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral